Laurion Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Laurion Capital Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-68,000	Closed	-$3.17M	–	728
2024 Q1	$3.17M	Buy	+68,000	New	+$3.21M	0.03%	298
2021 Q3	–	Sell	-2,918	Closed	-$278K	–	838
2021 Q2	$278K	Buy	+2,918	New	+$304K	﹤0.01%	600
2020 Q3	–	Sell	-6,848	Closed	-$536K	–	1099
2020 Q2	$536K	Buy	+6,848	New	+$453K	0.01%	605
2020 Q1	–	Sell	-17,515	Closed	-$748K	–	1025
2019 Q4	$748K	Sell	17,515 -9,685	-36%	-$400K	0.01%	622
2019 Q3	$1.16M	Buy	+27,200	New	+$1.48M	0.01%	613
2019 Q2	–	Sell	-19,823	Closed	-$1.38M	–	1130
2019 Q1	$1.38M	Buy	+19,823	New	+$1.13M	0.02%	462
2017 Q1	–	Sell	-2,900	Closed	-$204K	–	1530
2016 Q4	$204K	Buy	+2,900	New	+$206K	﹤0.01%	1001

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Laurion Capital Management's RARE Position: Q2 2024 in Review

Laurion Capital Management sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2024, closing a stake of 68,000 shares — an estimated $3.17M sold.

Laurion Capital Management first reported a position in RARE in Q4 2016 and held it in 7 quarters. The position peaked at $3.17M in Q1 2024. 275 funds tracked by Wall St. Rank hold RARE as of Q2 2024.

Laurion Capital Management reported no remaining Ultragenyx Pharmaceutical position as of Q2 2024 after selling out during the quarter.
Laurion Capital Management sold 68,000 Ultragenyx Pharmaceutical shares in Q2 2024, an estimated $3.17M.
Laurion Capital Management first reported a position in Ultragenyx Pharmaceutical in Q4 2016 and held it in 7 quarters.
Laurion Capital Management's Ultragenyx Pharmaceutical position peaked at $3.17M in Q1 2024.
275 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2024.

Based on Laurion Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.